Chikungunya
Therapeutic area
Infectious Disease
Rare disease
Yes
- Definition
- An infection that is caused by the Chikungunya virus, which is transmitted by mosquitoes; it is characterized by fever and severe arthralgia.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Chikungunya
- Therapeutic area
- Infectious Disease
- chikungunya
- Chikungunya fever
- Chikungunya virus caused disease or disorder
- Chikungunya virus disease or disorder
- Chikungunya virus infectious disease
- CHIK
- CHIKV infection
- CK
- Chikungunya virus infection
- arbovirus A Chikungunya type
- Disease mechanisms
- Acquired
- All therapeutic areas
- Infectious Disease
- Severity
- Moderate
- MONDO ID
- MONDO:0017941
- Parent condition
- MONDO:0005643
Related records
Broader conditions (11)
- Alphavirus infectious disease
- Arbovirus fever
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
- Primary viral infectious disease
- Togaviridae infectious disease
- Vector-borne disease
- Viral infectious disease
Trials (87)
- A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)
- A Clinical Study on the Efficacy and Safety of Reduning Injection in the Treatment of Chikungunya Fever
- A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue)
- A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents
- A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years
- A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)
- A Phase I Study of PepGNP-ChikV in Healthy Volunteers
- A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
- A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.
- A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children
- Against Chikungunya Virus and Neonatal Infection
- An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults
- Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
- Applying Wolbachia to Eliminate Dengue
- Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
- Baromètre Santé Adulte 2021-2022
- Chikungunya Arthritis in the Americas
- Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)
- Chikungunya Virus Detection in Semen
- Chikungunya Virus Vaccine Trial in Healthy Adults
Approved drugs (1)
- Chikungunya virus, live attenuated